With 1.04 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $71.99 whereas the lowest price it dropped to was $69.1. The 52-week range on SLNO shows that it touched its highest point at $74.00 and its lowest point at $36.93 during that stretch. It currently has a 1-year price target of $99.78. Beta for the stock currently stands at -2.43.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLNO was up-trending over the past week, with a rise of 2.00%, but this was up by 45.39% over a month. Three-month performance surged to 45.21% while six-month performance rose 33.46%. The stock gained 92.19% in the past year, while it has gained 58.84% so far this year. A look at the trailing 12-month EPS for SLNO yields -4.26 with Next year EPS estimates of -0.02. For the next quarter, that number is -0.93. This implies an EPS growth rate of 35.11% for this year and 99.34% for next year.
Float and Shares Shorts:
At present, 45.70 million SLNO shares are outstanding with a float of 36.40 million shares on hand for trading. On 2025-03-31, short shares totaled 4.66 million, which was 1016.0 higher than short shares on 1740700800. In addition to Dr. Anish Bhatnagar M.D. as the firm’s President, CEO, COO & Director, Mr. James H. MacKaness serves as its CFO & Compliance Officer.
Institutional Ownership:
Through their ownership of 1.12471 of SLNO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, SLNO reported revenue of $0.0 and operating income of -$58789000.0. The EBITDA in the recently reported quarter was -$49149000.0 and diluted EPS was -$1.27.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SLNO since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SLNO analysts setting a high price target of 123.0 and a low target of 81.0, the average target price over the next 12 months is 102.125. Based on these targets, SLNO could surge 72.27% to reach the target high and rise by 13.45% to reach the target low. Reaching the average price target will result in a growth of 43.03% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.8168 being high and -$3.95274 being low. For SLNO, this leads to a yearly average estimate of -$3.89. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
